IP Library Granted Patent US 9,890,382
Granted Patent B2
US 9,890,382 · App. 15/586,783 · Granted Feb 13, 2018

Nucleic acid compositions related to MIR-138-1-3P and uses thereof

Inventors: Itzhak Bentwich (Tel Aviv, IL); Amir Avniel (Tel Aviv, IL); Yael Karov (Tel Aviv, IL); Ranit Aharonov (Tel Aviv, IL)
Assignee: ROSETTA GENOMICS LTD.
C12N15/113C12Q1/6876C12N2310/141C12Q2600/178
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,890,382
App. No.
15/586,783
Granted
Feb 13, 2018
Kind
B2
Abstract

Described herein are polynucleotides associated with prostate and lung cancer. The polynucleotides are miRNAs and miRNA precursors. Related methods and compositions that can be used for diagnosis, prognosis, and treatment of those medical conditions are disclosed. Also described herein are methods that can be used to identify modulators of prostate and lung cancer.

Claims (17)

1. A nucleic acid selected from the group consisting of:

(a) a nucleic acid consisting of the nucleotide sequence set forth in SEQ ID NO: 4;

(b) a RNA encoded by the nucleic acid of (a), wherein the RNA is identical in length to (a);

(c) a nucleic acid at least 90% identical to (a) or (b); and

(d) the complement of one of the nucleic acids of (a)-(c), wherein the complement is identical in length to the one of the nucleic acids of (a)-(c);

wherein the nucleic acid contains a non-naturally occurring nucleotide or ribonucleotide.

2. A probe comprising a heterologous nucleic acid, wherein the heterologous nucleic acid consists of a nucleic acid sequence selected from the group consisting of:

(a) the sequence set forth in SEQ ID NO: 4;

(b) a RNA sequence encoded by the sequence of (a), wherein the RNA sequence is identical in length to (a);

(c) a sequence at least 90% identical to (a) or (b); and

(d) the complement of one of the sequences of (a)-(c), wherein the complement is identical in length to the one of the sequences of (a)-(c),

wherein the probe comprises at least one of a non-naturally occurring nucleotide or ribonucleotide, a label, and a solid substrate.

3. A vector comprising a heterologous nucleic acid, wherein the heterologous nucleic acid consists of a nucleic acid sequence selected from the group consisting of:

(a) the sequence set forth in SEQ ID NO: 4;

(b) a RNA sequence encoded by the sequence of (a), wherein the RNA sequence is identical in length to (a);

(c) a sequence at least 90% identical to (a) or (b); and

(d) the complement of one of the sequences of (a)-(c), wherein the complement is identical in length to the one of the sequences of (a)-(c).

Assignments (1)
SECURITY INTEREST Recorded Dec 15, 2017
From: ROSETTA GENOMICS INC.; ROSETTA GENOMICS LTD; MINUET DIAGNOSTICS, INC.; CYNOGEN INC.
To: GENOPTIX, INC.
Reel/Frame 044899/0237 →
Continuity (17)
Division 14756185 · Aug 13, 2015
Division 13986516 · May 8, 2013
Division 12661041 · Mar 10, 2010
Division 11130645 · May 16, 2005
Continuation PCTUS2005016986 · May 14, 2005
Continuation In Part 10709577 · May 14, 2004
Continuation In Part 10709572 · May 14, 2004
Provisional Application 60666340 · Mar 30, 2005
Provisional Application 60665094 · Mar 25, 2005
Provisional Application 60662742 · Mar 17, 2005
Provisional Application 60593329 · Jan 6, 2005
Provisional Application 60593081 · Dec 8, 2004
Provisional Application 60522860 · Nov 15, 2004
Provisional Application 60522457 · Oct 4, 2004
Provisional Application 60522449 · Oct 3, 2004
Provisional Application 60522452 · Oct 3, 2004
Related Publication 20170240894A1 · Aug 24, 2017